Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omadacycline - Paratek Pharmaceuticals

Next Previous
Drug Profile

Omadacycline - Paratek Pharmaceuticals

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; NUZYRA; PTK-0796; ZL 2401

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tufts University
  • Developer Merck & Co; Paratek Pharmaceuticals; ZAI Lab
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Skin and soft tissue infections
  • Preregistration Anthrax
  • Phase II Cystitis; Nontuberculous mycobacterium infections; Pyelonephritis; Urinary tract infections
  • Phase I Bacterial infections
  • No development reported Acute sinusitis; Plague
  • Discontinued Nosocomial infections

Most Recent Events

  • 05 Mar 2024 Preclinical trials in Anthrax in USA (Inhalation) prior to March 2024
  • 05 Mar 2024 Paratek Pharmaceuticals plans a meeting with US FDA to align on the final studies required to support the sNDA submission for both anthrax treatment and PEP indications in the middle of 2024
  • 05 Mar 2024 Paratek Pharmaceuticals plans to file sNDA to US FDA for Anthrax and post-exposure prophylaxis (PEP)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top